|
Sep 6
|
BridgeBio Pharma Announces Positive Feedback from the U.S. FDA and EU EMA on the Regulatory Path for a Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia
|
|
Aug 9
|
Wall Street Thinks BridgeBio Pharma Could Rise Over 40% -- But Will It?
|
|
Apr 27
|
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference
|